Harrow Health Q1 2024 Adj EPS $(0.28) Misses $(0.20) Estimate, Sales $34.600M Miss $37.268M Estimate
Portfolio Pulse from Benzinga Newsdesk
Harrow Health (NASDAQ:HROW) reported Q1 2024 adjusted EPS of $(0.28), missing the $(0.20) estimate, with sales of $34.600M also missing the $37.268M estimate. This represents a 32.55% increase in sales compared to the same period last year.
May 13, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Harrow Health's Q1 2024 earnings and sales missed estimates, with a significant 40% miss on EPS and a 7.16% miss on sales, despite a 32.55% increase in sales year-over-year.
Missing both EPS and sales estimates significantly, especially by 40% for EPS, is likely to negatively impact investor sentiment and stock price in the short term. The year-over-year sales increase may provide some buffer, but the immediate reaction to earnings misses tends to be negative.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100